Back to top
more

AngioDynamics (ANGO)

(Delayed Data from NSDQ)

$8.40 USD

8.40
310,287

-0.27 (-3.11%)

Updated Aug 6, 2025 04:00 PM ET

After-Market: $8.40 0.00 (0.00%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (148 out of 246)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Intuitive Surgical Shares May Rise as FDA Clears SureForm 45 Stapler

by Zacks Equity Research

ISRG secures FDA clearance for the first stapler designed for single-port robotic surgery, advancing minimally invasive procedures and enhancing surgical precision.

Zacks Equity Research

DexCom Shares May Rise as G7 15-Day CGM System Gets FDA Clearance

by Zacks Equity Research

DXCM secures FDA clearance for its G7 15-Day CGM, the longest-lasting and most accurate wearable, enhancing user convenience and expanding diabetes care access.

Zacks Equity Research

Here's Why You Should Retain Ecolab Stock in Your Portfolio Now

by Zacks Equity Research

ECL continues to gain from its robust product portfolio and strong segmental performance.

Zacks Equity Research

Is AngioDynamics (ANGO) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how AngioDynamics (ANGO) and ANIXA BIOSCIENCES INC (ANIX) have performed compared to their sector so far this year.

Zacks Equity Research

Neogen Stock Tumbles on Q3 Earnings & Sales Miss, Margins Contract

by Zacks Equity Research

NEOG posts lower-than-expected earnings and revenues for the third quarter of fiscal 2025.

Zacks Equity Research

Reasons to Retain QuidelOrtho Stock in Your Portfolio for Now

by Zacks Equity Research

QDEL continues to witness growth on the back of its strong product portfolio.

Zacks Equity Research

Telix Shares May Gain on the Distribution Deal With Cardinal Health

by Zacks Equity Research

TLX rolls out a new e-commerce platform connecting users to top retail pharmacies, aiming to boost savings, improve access, and expand its digital health services.

Zacks Equity Research

Walgreens Beats on Q2 Earnings, Withdraws Fiscal 2025 View, Stock Down

by Zacks Equity Research

WBA delivers better-than-expected earnings and revenues in the second quarter of fiscal 2025.

Zacks Equity Research

Wall Street Analysts Think AngioDynamics (ANGO) Could Surge 68.28%: Read This Before Placing a Bet

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 68.3% in AngioDynamics (ANGO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks Equity Research

AngioDynamics Stock Up on Q3 Earnings Beat, Gross Margin Expands

by Zacks Equity Research

ANGO reports solid fiscal third-quarter earnings with continued strength in its Med Tech segment. The expansion of gross margin bodes well.

Zacks Equity Research

AngioDynamics (ANGO) Tops Q3 Earnings and Revenue Estimates

by Zacks Equity Research

AngioDynamics (ANGO) delivered earnings and revenue surprises of 123.08% and 2%, respectively, for the quarter ended February 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Are Medical Stocks Lagging Gilead Sciences (GILD) This Year?

by Zacks Equity Research

Here is how Gilead Sciences (GILD) and AngioDynamics (ANGO) have performed compared to their sector so far this year.

Zacks Equity Research

MMSI Announces Commencement of Patient Enrollment in PREEMIE Study

by Zacks Equity Research

Merit Medical aims to improve care for vulnerable premature infants by evaluating the safety and efficacy of the Bloom Micro Occluder System for treating PDA in the specified patient pool.

Zacks Equity Research

InspireMD, Inc. (NSPR) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

InspireMD (NSPR) delivered earnings and revenue surprises of 5% and 6.50%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

The Cooper Companies (COO) Matches Q1 Earnings Estimates

by Zacks Equity Research

The Cooper Companies (COO) delivered earnings and revenue surprises of 0% and 1.71%, respectively, for the quarter ended January 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

AngioDynamics (ANGO) Down 14.2% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

AngioDynamics (ANGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

ANGO Stock Looks Promising on New Ischemia Study for Auryon System

by Zacks Equity Research

AngioDynamics initiates the AMBITION BTK RCT and registry to advance treatment for patients with chronic limb-threatening ischemia and below-the-knee peripheral artery disease.

Zacks Equity Research

AngioDynamics Stock Up on Q2 Earnings Beat, Gross Margin Declines

by Zacks Equity Research

ANGO registers overall strong top-line results on a pro-forma basis in second-quarter fiscal 2025, driven by strength in the Med Tech business.

Zacks Equity Research

AngioDynamics (ANGO) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

AngioDynamics (ANGO) delivered earnings and revenue surprises of 63.64% and 2.36%, respectively, for the quarter ended November 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

PDCO Stock Gains on the News of Acquisition Deal With Patient Square

by Zacks Equity Research

Patterson enters into a definitive agreement to be acquired by Patient Square Capital at a valuation of approximately $4.1 billion.

Zacks Equity Research

Baxter Stock May Gain Following Five New Injectable Product Launches

by Zacks Equity Research

BAX launches five new injectible products in the United States, thus further strengthening its U.S Pharmaceuticals business segment.

Zacks Equity Research

Reasons to Retain PacBio Stock in Your Portfolio for Now

by Zacks Equity Research

PACB continues to deliver growth from its unique technologies amid business seasonality concerns.

Zacks Equity Research

MBOT Stock Gains Following FDA Submission of the LIBERTY System

by Zacks Equity Research

Microbot Medical announces the submission of its LIBERTY System for FDA marketing clearance.

Zacks Equity Research

NSPR Stock May Gain as First Patient Enrolls in CGUARDIANS II Study

by Zacks Equity Research

InspireMD announces the first patient enrolment in the CGUARDIANS II clinical trial.

Zacks Equity Research

ANGO Stock Up Post FDA Nod for Prostate Tissue Ablation With NanoKnife

by Zacks Equity Research

AngioDynamics' latest regulatory approval is likely to pave the way for an alternative to conventional radical surgery and improve patient outcomes.